ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0462

Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis?

Sayuli Bhide1, Hannah Brubeck2, Punyasha Roul3, Aaron Baraff2, Bryant England4, Nadine El-Ayache1, Grant Cannon5, Namrata Singh6, Gary Kunkel7, Ted Mikuls4, Dolores Shoback8, Kaleb Michaud4, Patti Katz9, Jose Garcia10, Ariela Orkaby11, Joshua Baker12 and Katherine Wysham13, 1University of Washington, Seattle, WA, 2VA Puget Sound Health Care System, Seattle, WA, 3UNMC, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5University of Utah and Salt Lake City VA, Salt Lake City, UT, 6University of Washington, Bellevue, WA, 7University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 8San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, 9UCSF, San Rafael, CA, 10VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, 11Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Boston, MA, 12University of Pennsylvania, Philadelphia, PA, 13VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA

Meeting: ACR Convergence 2025

Keywords: Aging, gender, Mortality, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Frailty predicts mortality in RA. In the general population, males have a higher risk of death than females despite lower levels of frailty.1 We evaluated how sex modifies the relationship between frailty and mortality in RA.

Methods: Participants from the Veterans Affairs Rheumatoid Arthritis (VARA) Registry enrolled between 1/2003 to 12/2020 were included. Follow up ended in 12/2022, allowing for at least 2 years of observation for each participant. Frailty was measured annually throughout the observation period using the VA Frailty Index (VA-FI), a validated deficit accumulation score based on >6000 diagnostic codes.2 Participants were categorized as robust or frail at enrollment using the established VA-FI cutoff of >0.2. Our primary model used multivariable Cox regression to evaluate the relationship between baseline frailty and mortality, with sex as an interaction term. A subsequent multivariable Cox model, including only those who have new onset frailty, evaluated sex differences in the risk of death starting at the time of frailty onset. Models were adjusted for baseline age (categorized by decade), race, BMI (normal/low vs. high), RF positivity, RA disease duration, DAS28-ESR, rheumatic disease comorbidity index (RDCI), prednisone use, conventional synthetic DMARDs and biologic DMARDs.

Results: 2,601 males and 344 females were included in the primary analysis, with average age 66 (10) for males and 55 (12) for females. Disease duration was 11.6 (11.5) years for males and 9.8 (9.8) years for females. An equal proportion of males and females were frail at baseline (28% and 27%, respectively). During follow-up, 1,301 (50%) males and 66 (19%) females died. Compared to robust males, robust females were less likely to die (aHR 0.45, [0.32-0.63]). Frailty was associated with an increased risk of death in frail males compared to robust males (aHR 1.37, [1.20-1.57]). The risk of death did increase in frail females, however, it was not significantly higher than that of robust males (aHR 1.01, [0.70-1.45]). The risk of death conferred by frailty was higher in females than males as represented by the significant interaction term between sex and frailty of 1.64 (p=0.051). The incident frailty analysis included 948 males with mean age 67.6 (0.39) and 95 females with mean age 64.9 (2.43) with 526 (55%) males and 26 (27%) females dying during follow-up. Females with incident frailty were less likely to die than males with incident frailty (aHR 0.59, [0.39-0.91]). Median survival time was shorter in newly frail males than females (6.50 vs >16.40 years, respectively); exact median could not be calculated for females due to less than 50% death among females.

Conclusion: Frailty in RA is associated with mortality and this relationship differs by sex. Males, regardless of frailty status, have a higher risk of death than females, yet frailty confers a higher relative risk of death in females. Males with incident frailty have a higher risk of death and shorter median survival times than females with incident frailty with RA, highlighting the need for early recognition and intervention in this group.References:(1) Gordon et al. Exp Gerontol 2017 (2) Orkaby et al. TJ Gerontol A Biol Sci Med Sci 2019

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: S. Bhide: None; H. Brubeck: None; P. Roul: None; A. Baraff: None; B. England: Boehringer-Ingelheim, 2, 5; N. El-Ayache: None; G. Cannon: None; N. Singh: None; G. Kunkel: None; T. Mikuls: Amgen, 2, 5, Merck/MSD, 1, Olatech Therapeutics, 1, UCB, 1; D. Shoback: None; K. Michaud: None; P. Katz: None; J. Garcia: Aveo Oncology, 2, Catalym, 2, Pfizer, 5; A. Orkaby: None; J. Baker: Amgen, 5; K. Wysham: None.

To cite this abstract in AMA style:

Bhide S, Brubeck H, Roul P, Baraff A, England B, El-Ayache N, Cannon G, Singh N, Kunkel G, Mikuls T, Shoback D, Michaud K, Katz P, Garcia J, Orkaby A, Baker J, Wysham K. Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis? [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/does-biological-sex-affect-mortality-in-frail-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-biological-sex-affect-mortality-in-frail-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology